John O. Mascarenhas, MD, discusses the potential role of imetelstat in the treatment of patients with myelofibrosis.
John O. Mascarenhas, MD
Advertisement
John O. Mascarenhas, MD, is a professor of medicine at the Icahn School of Medicine at Mount Sinai; as well as director of the Center of Excellence for Blood Cancers and Myeloid Disorders, director of the Adult Leukemia Program, and a member of The Tisch Cancer Institute
Articles by John O. Mascarenhas, MD
John Mascarenhas, MD, outlines the ongoing phase 3 IMpact-MF trial, evaluating imetelstat in relapsed/refractory myelofibrosis.
John O. Mascarenhas, MD, discussed findings from the IMproveMF trial investigating imetelstat plus ruxolitinib in patients with higher-risk myelofibrosis.
John Mascarenhas, MD, discusses first-line treatment decisions for patients with myelofibrosis.
John O. Mascarenhas, MD, discusses evolution of JAK inhibitors in the treatment landscape of myelofibrosis.
John O. Mascarenhas, MD, discusses updates from the phase 2 MANIFEST trial in patients with myelofibrosis.
John O. Mascarenhas, MD, discusses the role of genetic testing in myeloproliferative neoplasms.
John O. Mascarenhas, MD, discusses the potential significance of pacritinib in patients with myelofibrosis.
John O. Mascarenhas, MD, discusses emerging agents in myelofibrosis.
John O. Mascarenhas, MD, discusses the need to develop curative therapies in myelofibrosis.
John O. Mascarenhas, MD, discusses the potential role of pacritinib in myeloproliferative neoplasms.
John O. Mascarenhas, MD, discusses the impact of ruxolitinib in the myelofibrosis treatment paradigm.
Advertisement
Latest Updated Articles
Dr Mascarenhas on the IMpact-MF Trial of Imetelstat in R/R MyelofibrosisPublished: September 26th 2025 | Updated:
Dr. Mascarenhas on the Potential Role of Pacritinib in MPNsPublished: September 10th 2020 | Updated:
Dr. Mascarenhas on the Need to Develop Curative Therapies in MyelofibrosisPublished: September 25th 2020 | Updated:
Dr. Mascarenhas on the Impact of Ruxolitinib on the Myelofibrosis Treatment ParadigmPublished: June 5th 2020 | Updated:
Dr. Mascarenhas on the Role of Genetic Testing in MPNsPublished: December 2nd 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5